Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients.

Cancers (Basel) · 2022 · PMC9496754 · PMID 36139644

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

showed a trendp = 0.059so close (0.05 < p ≤ 0.1)

MYSEC-PM showed a trend toward inferior PFS in intermediate-2 and high groups than the favorable and intermediate-1 group ( p = 0.059), which is consistent with the results of previous studies.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.